Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) subsidiary Jinzhou Aohong Pharmaceutical received the approval of China's drug administrator for its citrate-formulated novel drug FCN-437c in capsule form, according to a Thursday filing with the Shanghai bourse.
The approved indication is in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer following prior endocrine therapy.
Shares of the pharmaceutical company rose 4% in recent trade on the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.